MacroGenics reported $217.87M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Genmab DKK 12.87B 5.85B Dec/2025
Geron USD 534.12M 36.42M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Xencor USD 736.85M 138.65M Mar/2026